Sign in
Taking peoplePhase 3

Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

Key facts

Who runs it
Sanofi
Where
Belgium, France, Germany, Poland, Portugal, and Spain61 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
6,000 people, planned
Started
28 Oct 2026
Expected to end
28 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • IIV-HD (standalone)
  • NVXC19 (EU licensed, standalone)
  • IIV-HD + NVXC19 combination
  • Placebo, normal saline
Record updated
13 November 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Aged 60 years or older on the day of inclusion
  • Informed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
  • Aged 60 years or older on the day of inclusion
  • Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
  • Non-childbearing potential (i.e., post-menopausal for at least 1 year or surgically sterile)
  • lnformed consent form has been signed and dated
  • Able to attend all scheduled visits and to comply with all study procedures
  • Participant must be able to receive an injection in the deltoid muscle of both arms
  • Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine

Who cannot take part

  • Known/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
  • Any vaccine given within 4 weeks before or within 4 weeks after study intervention
  • Previous vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
  • Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
  • Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
  • Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved
  • History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
  • Personal or family history of Guillain-Barré syndrome
  • Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
  • Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
  • Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.

Read full original descriptionShow less

Study details include:

* The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01

The 2 groups in the trial

  • Group 1, IIV-HD and EU-licensed NVXC19Existing treatment, for comparison

    IIV-HD and NVXC19 co-administered in opposite deltoid muscles

    Treatment: IIV-HD (standalone) and NVXC19 (EU licensed, standalone)

  • Group 2, IIV-HD + NVXC19 combination and placeboTreatment being tested

    IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles

    Treatment: IIV-HD + NVXC19 combination and Placebo, normal saline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Record updated
13 November 2026